{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:46:44Z","timestamp":1758970004677},"reference-count":21,"publisher":"Informa Healthcare","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2007,1,1]]},"DOI":"10.1185\/030079907x242665","type":"journal-article","created":{"date-parts":[[2008,1,24]],"date-time":"2008-01-24T00:26:29Z","timestamp":1201134389000},"page":"3079-3089","source":"Crossref","is-referenced-by-count":3,"title":["Monthly dosing with risedronate 50\u2009mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study"],"prefix":"10.1185","volume":"23","author":[{"given":"Artur J.","family":"Racewicz","sequence":"first","affiliation":[{"name":"NZOZ Centrum Medyczne, BiaBystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Schofield","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Mason, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Cahall","sequence":"additional","affiliation":[{"name":"sanofi-aventis, Bridgewater, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Cline","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Mason, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Burgio","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Mason, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2007,11,12]]},"reference":[{"key":"CIT0001","unstructured":"National Osteoporosis Foundation. Disease facts [online]. Available from http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm\/ [last accessed 22 February 2007]"},{"key":"CIT0002","first-page":"1344","volume":"282","author":"Harris ST","year":"1999","journal-title":"Genant HK, et al.; for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc"},{"key":"CIT0003","first-page":"83","volume":"11","author":"Reginster J","year":"2000","journal-title":"on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int"},{"key":"CIT0004","first-page":"333","volume":"344","author":"McClung MR","year":"2001","journal-title":"for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103\u201311 [Epub 2002 June 27]","DOI":"10.1007\/s00223-002-2011-8"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.013"},{"key":"CIT0007","first-page":"522","volume":"12","author":"Ettinger MP","year":"2006","journal-title":"Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070083"},{"key":"CIT0009","unstructured":"FDA CDER. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Issued 4\/1994 [online]. Available from http:\/\/www.fda.gov\/cder\/guidance\/osteo.pdf\/ [last accessed 22 February 2007]"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.6.1051"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Delmas PD, Eastell R, Garnero P, et al.; for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(Suppl 6):S2\u2013S17","DOI":"10.1007\/s001980070002"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125003125"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129\u201335 [Epub 2003 December 5]","DOI":"10.1007\/s00223-003-0042-4"},{"key":"CIT0014","unstructured":"Burgio DE, Russell DA, Desliva B, et al. Risedronate pharmacokinetics following daily (5 mg\/day) and weekly (35 and 50 mg\/week) oral dosing regimens to postmenopausal women. Clin Pharmacol Ther 2002;71:32 [Abstract ID357]"},{"key":"CIT0015","first-page":"258","volume":"40","author":"Mitchell DY","year":"2000","journal-title":"Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol"},{"key":"CIT0016","first-page":"1906","volume":"83","author":"Singer FR","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"CIT0017","first-page":"51","volume":"22","author":"Hosking DJ","year":"1998","journal-title":"Chines AA. Paget\u2019s disease of bone: reduction of disease activity with oral risedronate. Bone"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00062-5"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.6.1032"},{"key":"CIT0020","first-page":"93","volume":"64","author":"Brown JP","year":"1999","journal-title":"Ste-Marie L, et al. Risedronate, a highly effective, short-term oral treatment for Paget\u2019s disease: a dose\u2013response study. Calcif Tissue Int"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1385\/JCD:6:1:45"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079907X242665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T07:19:31Z","timestamp":1599290371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079907X242665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,1,1]]}},"alternative-id":["10.1185\/030079907X242665"],"URL":"https:\/\/doi.org\/10.1185\/030079907x242665","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}